May Hill Capital LLC Takes $1.11 Million Position in Hologic, Inc. (NASDAQ:HOLX)

May Hill Capital LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,446 shares of the medical equipment provider's stock, valued at approximately $1,114,000.

Other large investors have also recently added to or reduced their stakes in the company. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment lifted its position in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HOLX. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Morgan Stanley decreased their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Stephens reiterated an "overweight" rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Finally, Argus downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average price target of $84.62.

Remove Ads

Hologic Trading Up 1.9 %

Shares of NASDAQ HOLX traded up $1.13 during midday trading on Thursday, reaching $61.69. The stock had a trading volume of 4,596,048 shares, compared to its average volume of 1,821,809. Hologic, Inc. has a twelve month low of $58.38 and a twelve month high of $84.67. The company's 50 day moving average price is $64.69 and its 200 day moving average price is $72.88. The firm has a market cap of $13.84 billion, a price-to-earnings ratio of 19.46, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.